3-2-2006

A Formal [3,3]-Sigmatropic Rearrangement Route to Quaternary α -Vinyl Amino Acids: Use of Allylic N-PMP Trifluoroacetimidates

David B. Berkowitz

University of Nebraska - Lincoln, dberkowitz1@unl.edu

Bin Wu

University of Nebraska - Lincoln

Huijie Li

University of Nebraska - Lincoln

Follow this and additional works at: <http://digitalcommons.unl.edu/chemistryberkowitz>

Part of the [Chemistry Commons](#)

Berkowitz, David B.; Wu, Bin; and Li, Huijie, "A Formal [3,3]-Sigmatropic Rearrangement Route to Quaternary α -Vinyl Amino Acids: Use of Allylic N-PMP Trifluoroacetimidates" (2006). *David Berkowitz Publications*. 9.
<http://digitalcommons.unl.edu/chemistryberkowitz/9>

This Article is brought to you for free and open access by the Published Research - Department of Chemistry at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in David Berkowitz Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Published in final edited form as:

Org Lett. 2006 March 2; 8(5): 971–974.

A Formal [3,3]-Sigmatropic Rearrangement Route to Quaternary α -Vinyl Amino Acids:

Use of Allylic *N*-PMP Trifluoroacetimidates

David B. Berkowitz, Bin Wu, and Huijie Li

Department of Chemistry, University of Nebraska, Lincoln, NE 68588-0304

Abstract

Pd(II)-mediated rearrangement of allylic *N*-PMP (*p*-methoxyphenyl) trifluoroacetimidates provides the first formal sigmatropic route to quaternary, α -vinylic amino acids, potential suicide substrates for PLP-enzymes. The amino acid side chains enter via transition metal-mediated C-C bond constructions, including (i) Cu(I)-mediated conjugate addition (Ala); (ii) Pd(0)/AsPh₃-mediated Stille coupling (Allyl-Gly, Phe, DOPA, *m*-Tyr) and (iii) Pd(0)/Pt-Bu₃-mediated Negishi coupling (Leu). In the synthesis of the DOPA decarboxylase inactivator, α -vinyl-*m*-tyrosine, the new *N*-PMP trifluoroacetimidate rearranges much more efficiently than the corresponding trichloroacetimidate.

Placing an unsubstituted vinyl group alpha to the amino group in an amino acid is an effective strategy for the suicide inactivation of some pyridoxal phosphate (PLP) enzymes. Examples include α -vinylglycine (naturally occurring), and vigabatrin (γ -vinyl-GABA), a synthetic antiepileptic drug, with exciting new potential for the treatment of substance abuse.¹ The principal mechanism by which the vinylic trigger is actuated, leading to an active site-directed Michael acceptor, is now established for both vinylglycine² and vigabatrin.³ These precedents continue to motivate the synthesis and testing of quaternary, α -vinyl amino acids, as candidates for the inactivation of amino acid decarboxylases (AADC's).⁴

The replacement of the α -hydrogen with a vinyl group builds specificity into the design, as it prevents PLP-dependent racemase, transaminase, and β - or γ -eliminase/replacement enzymes from actuating the trigger, yet allows for inclusion of the usual side chain for AADC recognition. The α -vinyl branch can subsequently be elaborated into halovinyl⁵ or oxiranyl⁶ groups, as potential triggering functionalities.

α -vinylglycine

(transaminases, ACC synthase)

vigabatrin (γ -vinyl-GABA)

(GABA transaminase)

Quaternary amino acids are also noteworthy targets for their ability to confer stability to proteases,⁷ promote helical structure,⁸ and serve as substrates for unnatural amino acid mutagenesis.⁹ The incorporation of unsaturation adds synthetic value.¹⁰ Given this, several synthetic approaches to quaternary, α -vinyl AA's have appeared, most using alkylative disconnections at the C α -vinylic¹¹ or C α -side chain¹² junctions.

We describe here a new entry into this unnatural AA class; namely, we disconnect at the C $_{\alpha}$ -N bond via a formal [3,3]-sigmatropic process (Scheme 1). To our knowledge, no examples of sigmatropic routes to quaternary α -vinyl AA's have previously appeared, though a high temperature, thermal allylic imidate rearrangement gives vinylglycinol.^{13,14} We had hoped to tap into the favorable O-C=N to O=C-N enthalpics to overcome the transformation of a trisubstituted olefin to a monosubstituted and sterically encumbered, quaternary vinyl group. Specifically, the Pd(II)-mediated allylic imidate rearrangement appeared attractive, as it proceeds under mild conditions and asymmetric variants have appeared, largely through the work of Overman.¹⁵ We are pleased to report that the *N*-PMP (*p*-methoxyphenyl) trifluoroacetimidate is particularly well suited for this transformation.^{16,17}

One distinguishing feature of a sigmatropic rearrangement approach to these unnatural AA's lies in the mode of side chain attachment. Previous approaches from our laboratory^{12a-c} and others^{12d,e} have used vinylglycine-derived AA enolates as the vehicles for side chain introduction. This chemistry usually requires strictly anhydrous conditions and low temperature.

As is illustrated in Schemes 2 and 3, the formal sigmatropic approach exploits transition metal-mediated C-C bond forming processes, at sp²- or sp-centers, for side chain installation. On the one hand, for α -vinylalanine, the side chain (Me) is carried in directly as part of a cuprate, thereby adding to the activated sp-center in **1**, under conditions described recently by Joullié.¹⁸ Alternatively, advantage was taken of higher order stannylcuprate chemistry pioneered by Lipshutz,¹⁹ again emanating from **1**, to access vinylstannanes **3** and **7**, and lay the foundation for Stille-based chemistry.

Stannane **3** also serves to provide a complementary vinyl iodide **4**,²⁰ for cross-couplings with the opposite sense of polarity. Indeed, the leucine side chain, as the isobutylzinc reagent, enters efficiently (73%) via Negishi-type coupling on this system. Best results were obtained with the Pd(P^{*t*}-Bu₃)₂ catalyst, under the Fu conditions.²¹ Cl₂Pd(dppf) was much less effective. Formation of the isobutylzinc reagent, via halogen-metal exchange from *i*-BuI, under the conditions recently disclosed by Smith (3 eq. *t*-BuLi, ZnCl₂)²² led to successful Negishi coupling, albeit in lower yields (30-35%). For benzylic and allylic side chains, a modified Pd-mediated Stille cross-coupling reaction,²³ on ester **7** or alcohol **3**, proceeded smoothly. In our hands, use of the AsPh₃ ligand generally gave very good results, though the DOPA system proved more difficult to handle.

With all six targeted AA side chains installed, the desired imidate rearrangement could be investigated. *N*-PMP-trifluoroacetimidoyl chloride is readily accessible²⁴ and provides for an exceedingly mild and efficient method for the introduction of the title imidate at -78 °C (Table 1). This is to be contrasted with the typical procedure for imidate installation by alcohol condensation with a nitrile in the presence of base (e.g. NaH, DBU) at rt.¹⁴

The *N*-PMP trifluoroacetimidate functionality was found to lead to clean rearrangement to the desired quaternary, protected α -amino alcohols, under Pd(II) catalysis, with all AA side chains examined (Table 1). Among Pd(II)-catalyst candidates examined, phosphine-coordinated complexes, such as Cl₂Pd(PPh₃)₂ or Cl₂Pd(dppf) gave little to no product. Provided that reactions were carried out in MeCN, Pd(OAc)₂ and PdCl₂ catalysts gave the desired formal [3,3]-sigmatropic rearrangement products. However, best results were obtained by starting from the preformed nitrile complex, either Cl₂Pd(NCMe)₂ or Cl₂Pd(NCPh)₂ in benzene solvent, whereby the latter complex generally produced more rapid conversion. The title imidate appears especially well suited to the construction of these hindered quaternary centers. Thus, in the important *m*-tyrosine system, direct NMR comparison (d₆-benzene) revealed that

the allylic *N*-PMP trifluoroacetimidate rearranges completely within one hour, whereas the corresponding trichloroacetimidate gives little to no product (Figure 1).

In these transformations, it proved auspicious to mask the latent α -carboxyl group as a THP ether. This protecting group is stable to the cuprate, Negishi or Stille side chain-couplings employed early, and leads to successful Pd(II) rearrangement. Moreover, immediately thereafter, we find that one can simultaneously cleave both the THP ether and the *N*-PMP group (CAN, MeCN, H₂O), following reductive (NaBH₄) removal of the trifluoroacetamide functionality (Table 2). This quickly yields α -vinyl amino alcohols, good vehicles for the introduction of Fmoc functionality. To our knowledge, this is first synthesis of quaternary α -vinyl AAs that outfits them with Fmoc protection.

Finally, Jones oxidation serves to complete the synthesis of the targeted *N*-Fmoc α -vinyl AA's, in a form appropriate for future peptide synthesis. Alternatively, should one wish to unveil the corresponding free α -vinyl AA's for study with PLP enzymes, one can cleave the Fmoc groups, by subjection to mildly basic conditions (TBAF at rt). We were particularly pleased to find that for **14c**, both the side chain OTIPS protecting group and the *N*-Fmoc group could be cleaved simultaneously in this way (Scheme 4), providing a novel synthesis of the known DOPA decarboxylase suicide substrate, **15c**. This work serves as proof of principle for a new allylic imidate rearrangement entry into quaternary α -vinyl amino acids, in the racemic series, and sets the stage for potential asymmetric variants of the approach, as well as for further applications of the interesting *N*-PMP trifluoroacetimidate to the installation of quaternary centers bearing nitrogen.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

We thank the NSF (CHE-0317083) and NIH (CA 62034) for support of our research program. Assistance from Kannan Karururichi, Weijun Shen, Xiang Shi and Sonia Bironneau-Gouault is acknowledged. This research was facilitated by shared instrumentation grants (NIH SIG-1-510-RR-06301, NSF CHE-0091975, NSF MRI-0079750).

References

- 1(a). Brodie JD, Figueroa E, Laska EM, Dewey SL. *Synapse* 2005;55:122–125. [PubMed: 15543630]
 (b) Brodie JD, Figueroa E, Dewey SL. *Synapse* 2003;50:261–265. [PubMed: 14515344]
2. Capitani G, Tschopp M, Eliot AC, Kirsch JF, Gruetter MG. *FEBS Lett* 2005;579:2458–2462. [PubMed: 15848188]
- 3(a). Czapinski P, Blaszczyk B, Czuczwar SJ. *Curr. Top. Med. Chem* 2005;5:3–14. [PubMed: 15638774]
 (b) Storici P, De Biase D, Bossa F, Bruno S, Mozzarelli A, Peneff C, Silverman RB, Schirmer T. *J. Biol. Chem* 2004;279:363–373. [PubMed: 14534310] (c) Nanavati SM, Silverman RB. *J. Am. Chem. Soc* 1991;113:9341–9349. (d) De Biase D, Barra D, Bossa F, Pucci P, John RA. *J. Biol. Chem* 1991;266:20056–20061. [PubMed: 1939068]
4. Berkowitz DB, Jahng W-J, Pedersen ML. *Bioorg. Med. Chem. Lett* 1996;6:2151–2156., and references therein.
- 5(a). Berkowitz DB, de la Salud-Bea R, Jahng W-J. *Org. Lett* 2004;6:1821–1824. [PubMed: 15151423]
 (b) Berkowitz DB, Pedersen ML, Jahng W-J. *Tetrahedron Lett* 1996;37:4309–4312.
6. Berkowitz DB, Pedersen ML. *J. Org. Chem* 1995;60:5368–5369.
7. Khosla MC, Stachowiak K, Smeby RR, Bumpus FM, Piriou F, Lintner K, Fermandjian S. *Proc. Natl. Acad. Sci. U. S. A* 1981;78:757–60. [PubMed: 6940144]
- 8(a). Yokum TS, Gauthier TJ, Hammer RP, McLaughlin ML. *J. Am. Chem. Soc* 1997;119:1167–1168.
 (b) Jaun B, Tanaka M, Seiler P, Kuhnle FNM, Braun C, Seebach D. *Liebigs Annalen/Recueil* 1997:1697–1710. (c) Aubry A, Bayeul D, Precigoux G, Pantano M, Formaggio F, Crisma M,

- Toniolo C, Boesten WHJ, Schoemaker HE, Kamphuis J. J. Chem. Soc., Perkin Trans. 2 1994:525–529.
9. Mendel D, Ellman J, Schultz PG. J. Am. Chem. Soc 1993;115:4359–4360.
10. Kaiser J, Kinderman SS, van Esseveldt BCJ, van Delft FL, Schoemaker HE, Blaauw RH, Rutjes FPJT. Org. Biomol. Chem 2005;3:3435–3467. [PubMed: 16172678]
- 11(a). Ma D, Zhu W. J. Org. Chem 2001;66:348–350. [PubMed: 11429926] (b) Petasis NA, Zavialov IA. J. Am. Chem. Soc 1997;119:445–446. (c) Pedersen ML, Berkowitz DB. J. Org. Chem 1993;58:6966–75. (d) Groth U, Schoellkopf U, Chiang YC. Synthesis 1982:864–866.
- 12(a). Berkowitz DB, Chisowa E, McFadden JM. Tetrahedron 2001;57:6329–6343. (b) Berkowitz DB, McFadden JM, Sloss MK. J. Org. Chem 2000;65:2907–2918. [PubMed: 10814177] (c) Berkowitz DB, McFadden JM, Chisowa E, Semerad CL. J. Am. Chem. Soc 2000;122:11031–11032. (d) Colson PJ, Hegedus LS. J. Org. Chem 1993;58:5918–5924. (e) Seebach D, Buerger HM, Schickli CP. Liebigs Annalen der Chemie 1991:669–684.
13. Vyas DM, Chiang Y, Doyle TW. J. Org. Chem 1984;49:2037–2039.
- 14(a). For examples of thermal rearrangements (typically refluxing toluene for days) of allylic trichloroacetimidates to access quaternary centers in the lactacystin class of natural products, see:Sato H, Maeba T, Yanase R, Yamaji-Hasegawa A, Kobayashi T, Chida N. J. Antibiot 2005;58:37–49. [PubMed: 15813179] (b) Oishi T, Ando K, Inomiya K, Sato H, Iida M, Chida N. Org. Lett 2002;4:151–154. [PubMed: 11772113] (c) Chida N, Takeoka J, Ando K, Tsutsumi N, Ogawa S. Tetrahedron 1997;53:16287–16298.
- 15(a). Anderson CE, Overman LE. J. Am. Chem. Soc 2003;125:12412–12413. [PubMed: 14531676] (b) Kang J, Yew KH, Kim TH, Choi DH. Tetrahedron Lett 2002;43:9509–9512. (c) Donde Y, Overman LE. J. Am. Chem. Soc 1999;121:2933–2934. (d) Uozumi Y, Kato K, Hayashi T. Tetrahedron: Asymmetry 1998;9:1065–1072. (e) Calter M, Hollis, Keith T, Overman LE, Ziller J, Zipp GG. J. Org. Chem 1997;62:1449–1456.
- 16(a). For preliminary descriptions of the behavior of the new allylic N-PMP trifluoroacetimidates and their application to the synthesis of quaternary, α -vinyl AA's via Pd(II)-mediated rearrangement, see:BerkowitzDBAbstract No. 6836th Midwest Regional American Chemical Society Meeting2001(b)LiHA New Approach to Quaternary Beta,Gamma-Unsaturated Amino Acids via a Formal [3,3]-Sigmatropic Rearrangement2001University of NebraskaM.S.
- 17(a). Subsequently, Overman and co-workers reported asymmetric, Pd(II)-rearrangements of N-PMP trifluoroacetimidates in non-quaternary model systems:Overman LE, Owen CE, Pavan MM, Richards CJ. Org. Lett 2003;5:1809–1812. [PubMed: 12762658] (b) Anderson CE, Donde Y, Douglas CJ, Overman LE. J. Org. Chem 2005;70:648–657. [PubMed: 15651813] (c) Prasad RS, Anderson CE, Richards CJ, Overman LE. Organometallics 2005;24:77–81.
18. Leonard MS, Carroll PJ, Joulle MM. J. Org. Chem 2004;69:2526–2531. [PubMed: 15049654]
- 19(a). Reginato G, Capperucci A, Degl'Innocenti A, Mordini A, Pecchi S. Tetrahedron 1995;51:2129–2136. (b) Lipshutz BH, Ellsworth EL, Dimock SH, Reuter DC. Tetrahedron Lett 1989;30:2065–2068.
20. Thibonnet J, Launay V, Abarbri M, Duchene A, Parrain J-L. Tetrahedron Lett 1998;39:4277–4280.
21. Dai C, Fu GC. J. Am. Chem. Soc 2001;123:2719–2724. [PubMed: 11456957]
22. Smith AB III, Beauchamp TJ, LaMarche MJ, Kaufman MD, Qiu Y, Arimoto H, Jones DR, Kobayashi K. J. Am. Chem. Soc 2000;122:8654–8664.
- 23(a). Sheffy FK, Godschalx JP, Stille JK. J. Am. Chem. Soc 1984;106:4833–4840. (b) Milstein D, Stille JK. J. Am. Chem. Soc 1979;101:4992–4998.
24. Tamura K, Mizukami H, Maeda K, Watanabe H, Uneyama K. J. Org. Chem 1993;58:32–5.

Figure 1.

Allylic imidate rearrangement, as monitored by ^1H NMR (d_6 -benzene): Panels (a) and (b) show allylic N-PMP trifluoroacetimidate **9c** and trichloroacetimidate **16c**, respectively, at $t = 0$. Panels (c) and (d) show NMR spectra of the same samples at $t = 1$ h, after exposure to 10 mol % $\text{PdCl}_2(\text{PhCN})_2$. In going from panel (a) to (c), the imidate methine proton in **9c** (br t, 6.0 ppm) is converted to the methine proton of the emerging vinyl group (dd, 5.8 ppm) in **10c**. Simultaneously, the allylic ether methylene in **9c** (2 H, 4.8 ppm) splits out into the *cis* (d, 1 H, 4.95 ppm) and *trans* (d, 1 H, 5.16 ppm) terminal vinylic protons of **10c**. These spectral snapshots attest to the efficiency with which the new quaternary center in the α -vinyl-*m*-tyrosine system is assembled, when the N-PMP trifluoroacetimidate is employed.

Scheme 1.
New Disconnection Toward Quaternary, α -Vinyl AAs

Scheme 2.

Introduction of the Ala and Leu Side Chains via Cuprate and Negishi Couplings

Scheme 3.

Side Chain Introduction via Modified Stille Couplings

Scheme 4.
Joint Fmoc/TIPS Deprotection to α -Vinyl-*m*-Tyr.

Table 1Allylic N-PMP Trifluoroacetimidate Installation/Rearrangement^a

entry	R	AA	yield of 9/10 ^b
a	Me	Ala	88/92% ^c
b	CH_2Ph	Phe	95/98% ^d
c	$\text{CH}_2(3'\text{-OTBS})\text{C}_6\text{H}_4$	<i>m</i> -Tyr	95/83% ^e
d	CH_2CHMe_2	Leu	98/83% ^b
e	$\text{CH}_2(3',4'\text{-bis-OTBS})\text{C}_6\text{H}_3$	DOPA	82/96% ^d
f	$\text{CH}_2\text{CH}=\text{CH}_2$	All-Gly	82/(70%), ^{cf}

^a Procedure: Imidate installations were initiated at -78°C in dry THF. Rearrangements were run in PhH at rt, until complete conversion to **10** was evident by TLC. **9a-f** designate the N-PMP allylic trifluoroacetimidates.

^b Isolated yields of purified rearrangement products [as THP diastereomers].

^c $\text{R}' = \text{Ph}$.

^d $\text{R}' = \text{Me}$.

^e In this case, the reaction is more rapid for the benzonitrile-based catalyst (see Fig. 1).

^f This yield is corrected for recovery of starting imidate (27%). Product **10f** itself was isolated in 51% yield.

Table 2

Protecting Group Interchange/Oxidation^a

entry	R	AA	11 ^b	12 ^c	13	14
a	Me	Ala	83%	--	51% ^d	79%
b	CH ₂ Ph	Phe	96%	63%	41%	90%
c	CH ₂ (3'-OTBS)C ₆ H ₄	<i>m</i> -Tyr	87% ^e	67%	78%	76%
d	CH ₂ CHMe ₂	Leu	67%	--	54% ^d	73%

^a Isolated yields of purified products are reported. **11a-d** denote the products of trifluoroacetamide deprotection. **12a-d** are the products of simultaneous *N*-PMP and THP deprotection. **13a-d** designate the *N*-Fmoc-protected amino alcohols.

^b These reactions typically involve addition of 5 eq. NaBH₄ in EtOH. at 0 °C, in portions, followed by warming to rt.

^c Yields here reflect cleavage of both the OTHP and *N*-PMP protecting groups.

^d In these cases, the crude amino alcohol was protected with Fmoc-OSu, so a two-step yield is given.

^e This yield reflects the installation of a more robust TIPS silyl protecting group (TBAF, then TIPSCl, imidazole), following rearrangement, in addition to trifluoroacetamide cleavage.